UCFA
CBAY

United Capital Financial Advisors’s Cymabay Therapeutics CBAY Stock Holding History

United Capital Financial Advisors’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-25,920
Closed -$52K – 1313
2016
Q2 		$52K Buy
+25,920
New +$53.8K ﹤0.01% 1231

Other funds holding CBAY

A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

United Capital Financial Advisors's CBAY Position: Q3 2016 in Review

United Capital Financial Advisors sold out of Cymabay Therapeutics (CBAY) in Q3 2016, closing a stake of 25,920 shares — an estimated $52K sold.

United Capital Financial Advisors first reported a position in CBAY in Q2 2016 and held it in 1 quarter. The position peaked at $52K in Q2 2016. 27 funds tracked by Wall St. Rank hold CBAY as of Q3 2016.

  • United Capital Financial Advisors reported no remaining Cymabay Therapeutics position as of Q3 2016 after selling out during the quarter.
  • United Capital Financial Advisors sold 25,920 Cymabay Therapeutics shares in Q3 2016, an estimated $52K.
  • United Capital Financial Advisors first reported a position in Cymabay Therapeutics in Q2 2016 and held it in 1 quarter.
  • United Capital Financial Advisors's Cymabay Therapeutics position peaked at $52K in Q2 2016.
  • 27 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q3 2016.

Based on United Capital Financial Advisors's 13F filing for Q3 2016, filed 14 Nov 2016.